Loading…
All American Wellness was cited for unlawfully selling unapproved and misbranded compounded drugs—specifically semaglutide and tirzepatide—over the internet to U.S. consumers. The company's website made false or misleading claims by marketing these compounded products as "Ozempic's compounded version" and "Mounjaro's compounded version," implying equivalence to FDA-approved drugs when compounded products are not FDA-approved. These marketing claims violated sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act by falsely representing unapproved compounded drugs as therapeutically equivalent to their brand-name counterparts. The FDA inspection of the company's website in August 2025 identified these misbranding violations, which constitute prohibited acts under section 301(a) of the FDCA.